27
Participants
Start Date
June 1, 2021
Primary Completion Date
October 5, 2022
Study Completion Date
October 5, 2022
FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
Participants exiting the TRAIT study will have received a 90-day supply of their current protocol-approved antidepressant treatment (ADT) if clinically appropriate, prior to entering the TRAIT-RS study, in addition to a continuity of care letter to be given to their medical provider to facilitate a refill of that medication as desired. (See NCT04748276 for specific formulary and prescribing guidelines).
Adams Clinical, Watertown
Lead Sponsor
Adams Clinical
NETWORK